• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form S-8 filed by Liquidia Corporation

    3/19/25 4:30:47 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $LQDA alert in real time by email
    S-8 1 tm259530d1_s8.htm FORM S-8

     

    As filed with the Securities and Exchange Commission on March 19, 2025

     

    Registration No. 333-        

     

     

    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    WASHINGTON, D.C. 20549

     

    FORM S-8

     

    REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933

     

    Liquidia Corporation
    (Exact name of registrant as specified in its charter)
       
    Delaware 85-1710962
    (State or other jurisdiction of
    incorporation or organization)
    (I.R.S. Employer Identification No.)
       
    419 Davis Drive, Suite 100
    Morrisville, North Carolina
    27560
    (Address of Principal Executive Offices) (Zip Code)
       
    liquidia corporation 2020 EMPLOYEE STOCK PURCHASE plan
    (Full title of the plan)
       
    Roger A. Jeffs, Ph.D.
    Chief Executive Officer
    Liquidia Corporation
    419 Davis Drive, Suite 100
    Morrisville, North Carolina
    (919) 328-4400
    Andrew P. Gilbert
    DLA Piper LLP (US)
    51 John F. Kennedy Parkway, Suite 120
    Short Hills, New Jersey
    (973) 520-2550
    (Name, address, telephone number,
    including area code, of agent for service)
    (Copy to)

     

    Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act. (Check one):

     

    Large accelerated filer ¨ Accelerated filer ¨ Non-accelerated filer x Smaller reporting company x Emerging growth company ¨

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act. ¨

     

     

     

     

     

     

    EXPLANATORY NOTE

     

    This Registration Statement on Form S-8 (this “Registration Statement”) is being filed for the purpose of registering an additional 150,000 shares of common stock, $0.001 par value per share (the “Common Stock”), of Liquidia Corporation (the “Registrant”) that were added to the shares authorized for issuance under the Liquidia Corporation Employee Stock Purchase Plan, as amended (the “ESPP”) for which a Registration Statement on Form S-8 relating to the same employee benefit plan is effective.

     

    On March 13, 2024 the Registrant filed the Registration Statement on Form S-8 (File No. 333-277881) with the Securities and Exchange Commission (the “Commission”), to register 150,000 shares of Common Stock that were authorized for issuance under the ESPP. On March 20, 2023 the Registrant filed the Registration Statement on Form S-8 (File No. 333-270698) with the “Commission, to register 150,000 shares of Common Stock that were authorized for issuance under the ESPP. On March 17, 2022, the Registrant filed the Registration Statement on Form S-8 (File No. 333-263664) with the Commission, to register 300,000 shares of Common Stock that were authorized for issuance under the ESPP. On November 18, 2020, the Registrant filed the Registration Statement on Form S-8 (File No. 333-250179) with the Commission, to register 300,000 shares of Common Stock that were authorized for issuance under the ESPP (collectively, the “Prior Registration Statements”). Upon the effectiveness of this Registration Statement, an aggregate of 1,050,000 shares of Common Stock will be registered for issuance from time to time under the ESPP. Pursuant to General Instruction E to Form S-8, the contents of the Prior Registration Statements are incorporated herein by reference except to the extent supplemented, amended or superseded by the information set forth herein. Only those items of Form S-8 containing new information not contained in the Prior Registration Statements are presented herein.

     

    INCORPORATION BY REFERENCE

     

    In accordance with General Instruction E to Form S-8, the contents of the Prior Registration Statements, with respect to securities offered pursuant to the ESPP, are hereby incorporated by reference.

     

    The following documents which have been filed by the Registrant with the Commission pursuant to the Securities Act and the Securities Exchange Act of 1934, as amended (the “Exchange Act”), are hereby incorporated herein by reference:

     

    (a)  The Registrant’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, filed with the Commission on March 19, 2025, pursuant to Section 13(a) of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), which contains the Registrant’s audited financial statements for the latest fiscal year for which such statements have been filed;

     

    (b)  All other reports filed pursuant to Section 13(a) or 15(d) of the Exchange Act since the end of the fiscal year covered by the Registrant’s Annual Report on Form 10-K referred to in (a) above; and

     

    (c)  The Registrant’s Current Report on Form 8-K12B filed with the Commission on November 18, 2020, including the description of Common Stock contained therein, including any amendments or reports filed for the purpose of updating such description.

     

    All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14 and 15(d) of the Exchange Act (except for any portions of the Registrant’s Current Reports on Form 8-K furnished pursuant to Item 2.02 or Item 7.01 thereof and any corresponding exhibits thereto not filed with the Commission), prior to the filing of a post-effective amendment which indicates that all securities offered have been sold or which deregisters all securities remaining unsold, shall be deemed to be incorporated by reference into this Registration Statement and to be a part of this Registration Statement from the date of filing of such documents.

     

    For purposes of this Registration Statement, any document or statement contained in a document incorporated or deemed to be incorporated by reference herein shall be deemed to be modified or superseded to the extent that a statement contained herein or in any other subsequently filed document which also is or is deemed to be incorporated by reference herein modifies or supersedes such document or statement in such document. Any such statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

     

     

     

     

    EXHIBIT INDEX

     

    EXHIBIT
    NUMBER
      DESCRIPTION
        
    4.1  Certificate of Incorporation of Liquidia Corporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Registration Statement on Form S-4, as amended (File No. 333-240421)).
        
    4.2  Certificate of Amendment of Certificate of Incorporation of Liquidia Corporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Quarterly Report on Form 10-Q, filed on August 10, 2023).
        
    4.3  Certificate of Second Amendment of Certificate of Corporation of Liquidia Corporation (incorporated by reference to Exhibit 3.1 of the Company’s Current Report on Form 8-K, filed with the SEC on June 21, 2024).
        
    4.4  Bylaws of Liquidia Corporation (incorporated by reference to Exhibit 3.2 of the Registrant’s Registration Statement on Form S-4, as amended (File No. 333-240421)).
        
    4.5  Form of Specimen Common Stock Certificate of Liquidia Corporation (incorporated by reference to Exhibit 4.1 of the Registrant’s Registration Statement on Form S-4, as amended (File No. 333-240421)).
        
    5.1  Opinion of DLA Piper LLP (US) (filed herewith).
        
    23.1  Consent of PricewaterhouseCoopers LLP, Independent Registered Public Accounting Firm (filed herewith).
        
    23.2  Consent of DLA Piper LLP (US) (contained in Exhibit 5.1).
        
    24.1  Power of Attorney (included on signature page).
        
    99.1  Liquidia Corporation 2020 Employee Stock Purchase Plan, and forms of award agreements thereunder (incorporated by reference to Exhibit 10.13 of the Registrant’s Registration Statement on Form S-4, as amended (File No. 333-240421)).
        
    99.2  Amendment No. 1 to the Liquidia Corporation 2020 Employee Stock Purchase Plan (incorporated by reference to Exhibit 10.36 of the Registrant's Annual Report on Form 10-K, filed on March 17, 2022).
        
    107  Filing Fee Table (filed herewith).

     

     

     

     

    SIGNATURES

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Morrisville, State of North Carolina, on March 19, 2025.

     

    LIQUIDIA CORPORATION  
       
    By: /s/ Roger A. Jeffs, Ph.D.  
      Name: Roger A. Jeffs, Ph.D.  
      Title: Chief Executive Officer    

     

    POWER OF ATTORNEY

     

    KNOW ALL MEN BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints each of Roger A. Jeffs, Ph.D. and Michael Kaseta his true and lawful attorney-in-fact, with full power of substitution and resubstitution for him and in his name, place and stead, in any and all capacities to sign any and all amendments including post-effective amendments to this Registration Statement on Form S-8 (including, without limitation, any additional registration statement filed pursuant to Rule 462 under the Securities Act of 1933), and to file the same, with all exhibits thereto, and other documents in connection therewith, with the Securities and Exchange Commission, hereby ratifying and confirming all that said attorney-in-fact or his substitute, each acting alone, may lawfully do or cause to be done by virtue thereof.

     

    Name Position Date
         
    /s/ Roger A. Jeffs, Ph.D. Chief Executive Officer and Director March 19, 2025
    Roger A. Jeffs, Ph.D. (Principal Executive Officer)  
         
    /s/ Michael Kaseta Chief Financial Officer and Chief Operating Officer March 19, 2025
    Michael Kaseta (Principal Financial Officer and Principal Accounting Officer)  
         
    /s/ Dr. Stephen Bloch Chairman of the Board of Directors March 19, 2025
    Dr. Stephen Bloch    
         
    /s/ Damian deGoa Director March 19, 2025
    Damian deGoa    
         
    /s/ Dr. Joanna Horobin Director March 19, 2025
    Dr. Joanna Horobin    
         
    /s/ David Johnson Director March 19, 2025
    David Johnson    
         
    /s/ Arthur Kirsch Director March 19, 2025
    Arthur Kirsch    
         
    /s/ Paul B. Manning Director March 19, 2025
    Paul B. Manning    
         
    /s/ Katherine Rielly-Gauvin Director March 19, 2025
    Katherine Rielly-Gauvin    
         
    /s/ Raman Singh Director March 19, 2025
    Raman Singh    

     

    Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed by the following persons in the capacities and on the dates indicated.

     

     

     

    Get the next $LQDA alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $LQDA

    DatePrice TargetRatingAnalyst
    10/20/2025$31.00Overweight
    Wells Fargo
    8/15/2025$43.00Buy
    Jefferies
    5/19/2025$13.00Perform → Underperform
    Oppenheimer
    12/20/2024$20.00Overweight
    Wells Fargo
    10/16/2024Sector Outperform
    Scotiabank
    8/19/2024Outperform → Strong Buy
    Raymond James
    8/16/2024$27.00Outperform
    Raymond James
    6/25/2024Perform
    Oppenheimer
    More analyst ratings

    $LQDA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Wells Fargo initiated coverage on Liquidia Technologies with a new price target

    Wells Fargo initiated coverage of Liquidia Technologies with a rating of Overweight and set a new price target of $31.00

    10/20/25 8:01:49 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Liquidia Technologies with a new price target

    Jefferies resumed coverage of Liquidia Technologies with a rating of Buy and set a new price target of $43.00

    8/15/25 7:59:34 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Technologies downgraded by Oppenheimer with a new price target

    Oppenheimer downgraded Liquidia Technologies from Perform to Underperform and set a new price target of $13.00

    5/19/25 8:49:50 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Chief Accounting Officer Boyle Dana sold $65,807 worth of shares (1,580 units at $41.65), decreasing direct ownership by 0.88% to 178,848 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    1/28/26 4:30:53 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Adair Jason sold $28,655 worth of shares (688 units at $41.65), decreasing direct ownership by 0.32% to 211,169 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    1/28/26 4:30:16 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Business Officer Adair Jason was granted 27,683 shares, increasing direct ownership by 15% to 211,857 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    1/21/26 6:28:30 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Liquidia Corporation

    SCHEDULE 13G/A - Liquidia Corp (0001819576) (Subject)

    2/9/26 8:56:46 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - Liquidia Corp (0001819576) (Filer)

    1/9/26 6:30:35 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 144 filed by Liquidia Corporation

    144 - Liquidia Corp (0001819576) (Subject)

    11/18/25 4:23:03 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Manning Paul B bought $2,999,994 worth of shares (337,078 units at $8.90) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/16/24 4:05:20 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Caligan Partners Lp disposed of 3,440,948 shares, sold $1,426,500 worth of shares (150,000 units at $9.51) and bought $1,426,500 worth of shares (150,000 units at $9.51) (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    9/4/24 5:51:34 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jeffs Roger bought $1,000,001 worth of shares (139,665 units at $7.16), increasing direct ownership by 28% to 640,805 units (SEC Form 4)

    4 - Liquidia Corp (0001819576) (Issuer)

    12/18/23 5:02:01 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Liquidia to Present Clinical Data Across Its Portfolio at the Pulmonary Vascular Research Institute 2026 Annual Congress

    MORRISVILLE, N.C., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company revolutionizing care for patients with challenging respiratory and vascular diseases, announced today the company will present three posters at the Pulmonary Vascular Research Institute (PVRI) 2026 Annual Congress to be held January 28 through February 1, 2026, in Dublin, Ireland. The presentations highlight clinical data in pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD) with LIQ861, approved in the United States as YUTREPIA™ (treprostinil) inhalation powder, and L606, an investigational extended-release fo

    1/27/26 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Announces Preliminary Full-Year 2025 YUTREPIA Net Sales and Corporate Update

    Estimated YUTREPIA™ net product sales of approximately $90.1 million in the fourth quarter and $148.3 million for full-year 2025Received more than 2,800 unique patient prescriptions since launch in June 2025Generated more than $30 million of positive cash flow during the fourth quarter 2025 MORRISVILLE, N.C., Jan. 09, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced preliminary, unaudited full-year 2025 net product sales of YUTREPIA™ (treprostinil) inhalation powder, as well as updates on the commercial launch and

    1/9/26 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Present at 44th Annual J.P. Morgan Healthcare Conference

    MORRISVILLE, N.C., Jan. 07, 2026 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) announced today that Dr. Roger Jeffs, Chief Executive Officer, will present at the 44th Annual J.P. Morgan Healthcare Conference on Wednesday, January 14, 2026 beginning at approximately 5:15 p.m. Pacific Time (8:15 p.m. Eastern Time) at the Westin St. Francis in San Francisco, California. Access to a live, audio-only webcast will be available on the "Investors" page of Liquidia's website at https://liquidia.com/investors/events-and-presentations. The webcast will be archived on the company's website for at least 30 days. About Liquidia CorporationLiquidia Corporation is a biopharmaceutical company dr

    1/7/26 7:00:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    FDA approvals

    Live FDA approvals issued by the Food and Drug Administration and FDA breaking news

    View All

    FDA Tentative Approval for YUTREPIA issued to Liquidia Technologies, Inc.

    Submission status for Liquidia Technologies, Inc.'s drug YUTREPIA (ORIG-1) with active ingredient TREPROSTINIL has changed to 'Tentative Approval' on 11/04/2021. Application Category: NDA, Application Number: 213005, Application Classification: Type 3 - New Dosage Form

    11/18/21 2:49:33 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Liquidia Corporation

    SC 13G/A - Liquidia Corp (0001819576) (Subject)

    11/12/24 5:35:19 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/12/24 4:22:57 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13D/A filed by Liquidia Corporation

    SC 13D/A - Liquidia Corp (0001819576) (Subject)

    9/4/24 5:51:42 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Leadership Updates

    Live Leadership Updates

    View All

    Atea Pharmaceuticals Appoints Arthur S. Kirsch to Board of Directors

    BOSTON, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) (Atea or Company), a clinical-stage biopharmaceutical company engaged in the discovery and development of oral antiviral therapeutics for serious viral diseases, today announced the appointment of Arthur S. Kirsch to the Company's Board of Directors, effective immediately. Mr. Kirsch has decades of experience in investment banking and capital markets, as well as extensive knowledge of the healthcare and life sciences industries. Mr. Kirsch is currently a Senior Advisor with Alvarez & Marsal's Life Sciences Industry Group, and over the course of his 30-year career has held numerous roles in mergers and acqui

    2/24/25 7:00:00 AM ET
    $AVIR
    $LQDA
    $KDMN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Major Pharmaceuticals

    Emergent BioSolutions Names Two Pharmaceutical Industry Veterans to Board of Directors

    GAITHERSBURG, Md., Oct. 02, 2023 (GLOBE NEWSWIRE) -- Emergent BioSolutions Inc. (NYSE:EBS) today announced the appointment of Neal Fowler and Don DeGolyer to its Board of Directors effective October 1, 2023, with initial terms expiring at Emergent's 2024 Annual Meeting of Stockholders. Both joined as independent directors and bring more than 70 years of combined biopharmaceutical industry and sales experience. "Neal and Don bring unique and extensive expertise to Emergent as the company defines its future in this post-pandemic environment," said Emergent Chairman Dr. Zsolt Harsanyi, Ph.D. "Maintaining our focus on our mission of protecting and enhancing life, these industry veterans add v

    10/2/23 7:00:00 AM ET
    $EBS
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)

    MORRISVILLE, N.C., July 21, 2022 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA) today announced that, in connection with the previously announced appointment of Rajeev Saggar, M.D., Liquidia's new Chief Medical Officer, it has agreed to grant him an employment inducement equity award. As previously disclosed in a Current Report on Form 8-K filed with the Securities and Exchange Commission on June 22, 2022 ("Form 8-K"), Liquidia has agreed to grant Dr. Saggar initial equity awards upon his commencement of employment, which includes a stock option exercisable for 200,000 shares of Liquidia's common stock under the Liquidia Corporation 2022 Inducement Plan (the "Inducement Plan"). The

    7/21/22 4:30:00 PM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $LQDA
    Financials

    Live finance-specific insights

    View All

    Liquidia Corporation Reports Third Quarter 2025 Financial Results and Provides Corporate Update

    Recorded $51.7 million in net product sales of YUTREPIA™ as launch momentum continuesAchieved profitability in the first full quarter of YUTREPIA salesMore than 2,000 unique patient prescriptions and 1,500 patient starts to dateCompany to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company driven by science and compassion to revolutionize care for patients with challenging respiratory and vascular diseases, today announced its financial results for the third quarter ended September 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern Time on November 3, 2025, to review financ

    11/3/25 6:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation to Report Third Quarter 2025 Financial Results on November 3, 2025

    MORRISVILLE, N.C., Oct. 27, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary disease, announced today that it will report its third quarter 2025 financial results on Monday, November 3, 2025. The company will host a webcast at 8:30 a.m. Eastern Time to discuss its financial results and provide a corporate update. The webcast will be available on Liquidia's website at https://liquidia.com/investors/events-and-presentations. A rebroadcast of the event will be available and archived for a period of one year at the same location. About Liquidia CorporationLiquidia Corporation is a b

    10/27/25 8:30:00 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Liquidia Corporation Reports Second Quarter 2025 Financial Results and Provides Corporate Update

    YUTREPIA™ surpasses 900 unique patient prescriptions and 550 patient starts within 11 weeks after approval to treat PAH and PH-ILDPositive interim data from ASCENT trial reinforces YUTREPIA's tolerability and efficacy profile in PH-ILD with median improvement in six-minute walk distance of 31.5 meters at Week 16Company to host webcast today at 8:30 a.m. ET MORRISVILLE, N.C., Aug. 12, 2025 (GLOBE NEWSWIRE) -- Liquidia Corporation (NASDAQ:LQDA), a biopharmaceutical company developing innovative therapies for patients with rare cardiopulmonary diseases, today announced its financial results for the second quarter ended June 30, 2025. The company will also host a webcast at 8:30 a.m. Eastern

    8/12/25 6:30:45 AM ET
    $LQDA
    Biotechnology: Pharmaceutical Preparations
    Health Care